Fieldview Capital Management LLC Acquires Shares of 1,871 IDEXX Laboratories, Inc. $IDXX

Fieldview Capital Management LLC acquired a new stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the 4th quarter, Holdings Channel.com reports. The fund acquired 1,871 shares of the company’s stock, valued at approximately $1,266,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of IDXX. Beacon Investment Advisory Services Inc. grew its holdings in shares of IDEXX Laboratories by 11.9% during the fourth quarter. Beacon Investment Advisory Services Inc. now owns 62,951 shares of the company’s stock valued at $42,588,000 after purchasing an additional 6,710 shares during the last quarter. Nordea Investment Management AB grew its holdings in shares of IDEXX Laboratories by 114.1% during the fourth quarter. Nordea Investment Management AB now owns 16,597 shares of the company’s stock valued at $11,283,000 after purchasing an additional 8,845 shares during the last quarter. NEOS Investment Management LLC grew its holdings in shares of IDEXX Laboratories by 82.7% during the third quarter. NEOS Investment Management LLC now owns 30,051 shares of the company’s stock valued at $19,199,000 after purchasing an additional 13,599 shares during the last quarter. Procyon Advisors LLC bought a new position in shares of IDEXX Laboratories during the fourth quarter valued at approximately $1,966,000. Finally, Diversified Trust Co. grew its holdings in shares of IDEXX Laboratories by 223.5% during the fourth quarter. Diversified Trust Co. now owns 4,199 shares of the company’s stock valued at $2,841,000 after purchasing an additional 2,901 shares during the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the company. Citigroup assumed coverage on IDEXX Laboratories in a report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price objective for the company. UBS Group decreased their price objective on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a report on Tuesday, April 28th. Stifel Nicolaus decreased their price objective on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a report on Tuesday, March 31st. Weiss Ratings lowered IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a report on Monday, May 11th. Finally, Wall Street Zen raised IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Saturday. Seven equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, IDEXX Laboratories has an average rating of “Moderate Buy” and a consensus target price of $751.00.

IDEXX Laboratories Stock Performance

IDXX opened at $560.88 on Monday. The company has a market capitalization of $44.24 billion, a price-to-earnings ratio of 41.30, a price-to-earnings-growth ratio of 3.07 and a beta of 1.56. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.12 and a quick ratio of 0.82. IDEXX Laboratories, Inc. has a 1-year low of $506.91 and a 1-year high of $769.98. The business has a 50 day moving average price of $563.06 and a two-hundred day moving average price of $626.82.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, beating analysts’ consensus estimates of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The company had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.12 billion. During the same quarter in the prior year, the firm earned $2.91 EPS. The company’s quarterly revenue was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Research analysts predict that IDEXX Laboratories, Inc. will post 14.68 EPS for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.